Does bacterial vaginosis affect the success of an embryo transfer in IVF patients?

Does Bacterial Vaginosis Impact Embryo Transfer Success?

Yes, bacterial vaginosis (BV) significantly impairs embryo transfer outcomes, particularly increasing early pregnancy loss and reducing clinical pregnancy rates, and should be screened for and treated before IVF procedures.

Evidence for Impact on IVF Outcomes

The most recent and highest quality evidence demonstrates clear adverse effects of vaginal dysbiosis on reproductive outcomes:

Recent meta-analyses show that vaginal dysbiosis, including BV:

• Increases early pregnancy loss by 49% (RR = 1.49,95% CI 1.15-1.94) 1
• Reduces clinical pregnancy rates by 18% (RR = 0.82,95% CI 0.70-0.95) 1
• Shows a 71% increased risk of early pregnancy loss across all diagnostic methods (RR = 1.71,95% CI 1.29-2.27) 2

A 2024 prospective study found even more striking results:

• Normal vaginal flora achieved 84.3% clinical pregnancy rate versus 34.2% with severe dysbiosis 3
• Miscarriage rates were dramatically higher: 1.3% (normal) versus 21.1% (severe dysbiosis) 3
• Ongoing pregnancy rates: 83.1% (normal) versus 27% (severe dysbiosis) 3

Most compellingly, a 2026 prospective study demonstrated:

• Catheter contamination with non-Lactobacillus organisms was the only independent factor associated with IVF failure 4
• Pregnancy rates: 8.5% (contaminated) versus 39.6% (clean) 4
• Live birth rates: 4.2% (contaminated) versus 24.4% (clean) 4

Mechanism of Impact

BV-associated bacteria have been recovered from the endometrium and fallopian tubes of women with pelvic inflammatory disease 5, 6. The bacterial flora characteristic of BV creates an inflammatory environment that:

• Contaminates the embryo transfer catheter in up to 58% of cases 4
• Disrupts endometrial receptivity
• Increases risk of ascending infection

The prevalence of BV in IVF populations ranges from 18-26% 1, 2, 7, making this a common and clinically significant issue.

Clinical Recommendations

Screening Protocol

Screen all IVF patients for BV before embryo transfer using:

• Clinical criteria (Amsel criteria): vaginal pH >4.5, clue cells, fishy odor, homogeneous discharge—requires 3 of 4 findings 8
• Gram stain (Nugent score) for more objective assessment 8, 3
• Consider molecular methods (qPCR, 16S rRNA sequencing) for enhanced detection 2, 4

Treatment Regimen

For women with confirmed BV before IVF:

First-line treatment:

• Metronidazole 500 mg orally twice daily for 7 days 5, 6

Alternative regimens:

• Metronidazole gel 0.75%, one applicator (5g) intravaginally daily for 5 days 5
• Clindamycin cream 2%, one applicator (5g) intravaginally at bedtime for 7 days 5

Important treatment considerations:

• Avoid alcohol during metronidazole treatment and for 24 hours after 5, 6
• Clindamycin cream is oil-based and may weaken latex condoms 5, 6
• Treatment of male partners should be considered for recurrent BV 9, 10

Timing

• Screen during the cycle preparation phase, before controlled ovarian stimulation if possible
• Note that controlled ovarian stimulation itself can shift vaginal microbiota toward dysbiosis 11
• Retest after treatment to confirm resolution before proceeding with transfer

Critical Caveats

The evidence shows a puzzling pattern: BV impacts clinical pregnancy rates and early pregnancy loss but studies have not consistently shown impact on live birth rates 1. This may reflect:

• Study design limitations (many don't follow patients to delivery)
• Sample size issues for detecting live birth differences
• The fact that most pregnancy losses occur early

However, the 2024 Chinese study using Nugent scoring showed clear live birth rate differences (83.1% normal versus 27% severe dysbiosis) 3, and the 2026 catheter contamination study showed definitive live birth impacts 4.

Practical Algorithm

1. Screen all IVF patients for BV using clinical criteria or Gram stain before starting treatment cycle
2. If BV positive: Treat with metronidazole 500 mg PO BID × 7 days
3. Retest 1-2 weeks after treatment to confirm cure
4. If persistent BV: Consider alternative regimen or partner treatment
5. Only proceed with embryo transfer once normal vaginal flora is restored
6. If emergency transfer needed with untreated BV: Counsel patient about 2-4× increased miscarriage risk

The evidence strongly supports that BV is not merely an incidental finding but a modifiable risk factor that substantially impairs IVF success 3, 4. Given the high cost and emotional burden of IVF, screening and treatment represent a low-cost, high-impact intervention.